The results of the latest diabetes-prevention trial, DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication), announced recently how the trial reduced the risk of developing type 2 diabetes by 62 percent relative to placebo among people at high risk of developing type 2 diabetes.
The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) trial evaluated the likelihood of progression to type-2 diabetes over a three-year period among 5,269 people with a condition known as “pre-diabetes.”1 In pre-diabetes, blood sugar levels are higher than normal, but not yet high enough for a diagnosis of type 2 diabetes.
Pre-diabetes is considered a key stage in the development of type 2 diabetes – a chronic, progressive illness often linked to premature death that affects approximately 230 million individuals worldwide and is expected to affect 350 million people globally by 2025. In fact, more than three million people die from diabetes-related causes each year – one death every 10 seconds. In the UAE, diabetes affects more than 20% of the adult population, making this disease four times more prevalent than worldwide figures.
Presented at the annual European Association for the Study of Diabetes, the study was designed and conducted by the Population Health Research Institute at McMaster University and showed that 10.6 percent of people receiving rosiglitazone progressed to type 2 diabetes as against 25 percent of people treated with placebo.
“The DREAM finding is particularly significant for the Middle East region, especially for UAE whose population is largely prone to diabetes due to the high rate of obesity recorded in the country. One third of the UAE population now has diabetes type 2 and by 2010 that number is expected to have risen to half of the UAE’s population,” commented Dr. Abdul Razzaq Al Madani, Director at the Dubai Hospital and Chairman of the UAE Diabetes Society, who attended the annual meeting.
“This study provides groundbreaking research for the treatment of pre-diabetes in order to improve lives of patients and avert risks of those patients in the initial stage. This is an important discovery that can help better understand diabetes and its treatment,” said Dr. Madani.
“GSK is committed to groundbreaking research for the treatment of pre-diabetes and type-2 diabetes in order to improve patient outcomes. We believe the long awaited findings from the DREAM trial will lead to a better understanding of type-2 diabetes and its treatment,” said Dr. Lawson Macartney, senior vice president, Cardiovascular and Metabolic Medicine Development Centre, GlaxoSmithKline.
“The DREAM trial is the largest diabetes prevention trial conducted to date and provides the first body of evidence that rosiglitazone can reduce the risk of progression from pre-diabetes to type-2 diabetes in high risk patients,” Macartney concluded.